OOIR: Observatory of International Research

Papers

(The H4-Index of Journal for Immunotherapy of Cancer is 72. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death	537
TIGIT in cancer immunotherapy	369
Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB H	305
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events	287
LAG-3: from molecular functions to clinical applications	248
Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future	241
Tim-3 finds its place in the cancer immunotherapy landscape	223
Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity	209
Clinical landscape of oncolytic virus research in 2020	183
Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinica	148
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events	131
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial	130
Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometri	127
Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial	125
The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation	123
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice	122
ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma	121
Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?	119
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce	117
Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition	117
HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy	113
Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing	106
STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation	102
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma	100
Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer	99

Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation	98
Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma	98
Phagocytic function of tumor-associated macrophages as a key determinant of tumor progression control: a review	98
Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer	98
Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies	97
M1^hottumor-associated macrophages boost tissue-resident memory T cells infiltration and survival in human lung cancer	95
Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes	95
Acute kidney injury in patients treated with immune checkpoint inhibitors	94
Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer	92
Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers	91
Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer	91
Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer	90
Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy	89
Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma	89
IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma	89
Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer	88
Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead	88
Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial	86
Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker	85
Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer	85
CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer	83
Phase 2 study of pembrolizumab in patients with advanced rare cancers	82
Therapeutic depletion of CCR8⁺tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy	82
Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial	81
Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study	81
Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma	81
Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial	81
Intratumoral CXCL13⁺CD8⁺T cell infiltration determines poor clinical outcomes and immunoevasive contexture in patients with clear cell renal cell carcinoma	81
Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma	79
Tumor-draining lymph node is important for a robust abscopal effect stimulated by radiotherapy	78
Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers	78
Compound kushen injection relieves tumor-associated macrophage-mediated immunosuppression through TNFR1 and sensitizes hepatocellular carcinoma to sorafenib	78
Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy	77
Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial	77
Intratumoral TIGIT⁺ CD8⁺ T-cell infiltration determines poor prognosis and immune evasion in patients with muscle-invasive bladder cancer	76
PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations	76
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemothera	76
A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone	76
Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up	75
Rethinking immune checkpoint blockade: ‘Beyond the T cell’	74
Mitochondrial Lon-induced mtDNA leakage contributes to PD-L1–mediated immunoescape via STING-IFN signaling and extracellular vesicles	73
Inhibition of TGF-β-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer	73
Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC	73
Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors	73
Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors	73
Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1	73
ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy	72